Posts by Immunexpress
In the news: Why Better Sepsis Diagnosis Results in Better Outcomes at CLP
Why Better Sepsis Diagnosis Results in Better Outcomes From the CLP article by By Silvia Cermelli, PhD, and Prashant Wani, PhD: Making a Breakthrough in Rapid Sepsis Diagnosis Immunexpress’s SeptiCyte RAPID measures host response to differentiate sepsis from non-infectious systemic inflammation (i.e., SIRS). It is an FDA cleared test for this purpose and has a…
Read MoreIn the news: Septicyte RAPID test mentioned in Infection Control Today
From the article in Infection Control Today SeptiCyte RAPID test Sepsis is an overwhelming immune response to infection that can be life-threatening. Immunexpress’ SeptiCyte RAPID test is meant to ensure the timely and accurate diagnosis of sepsis, which is critical to allow clinicians to rapidly make correct treatment decisions that can improve prognoses and save…
Read MoreImmunexpress to Present Data at ECCMID 2023 Indicating that SeptiCyte® RAPID Differentiates Sepsis from Non-Sepsis in Patients with Uncertain Initial Diagnosis
This post originally appeared on Cision PR Newswire SEATTLE and BRISBANE, Australia, April 5, 2023 /PRNewswire/ — Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, announced today a poster presentation at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) which evaluates the use of SeptiCyte® RAPID as a tool to determine…
Read MoreRollie Carlson Ph. D podcast interview with Tom Hickey of Med Tech Gurus
Immunexpress to Present Data at ISICEM 2023 Indicating that SeptiCyte® RAPID Outperforms Other Rapid Measures for Sepsis Diagnosis
Immunexpress Begins US Commercialization of Sepsis Diagnostic Test
New Publication Validates SeptiCyte® RAPID as a Triaging Tool for COVID-19 Patients
SeptiCyte RAPID accurately assessed COVID-19 severity Elevated SeptiScore upon hospital intake was predictive of ICU admission SeptiCyte RAPID performed better than single-biomarker assays that are routinely used to assess COVID-19 severity SEATTLE and BRISBANE, Australia, Feb. 2, 2023 /PRNewswire/ — Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients,…
Read MoreAt AMP 2022, Immunexpress launches rapid test for sepsis requiring two minutes hands-on time
From Leo O’Connor of LabPulse.com At the Association for Molecular Pathology annual meeting and exposition this week, Immunexpress launched a rapid molecular diagnostic test that could enable ruling in or ruling out sepsis in one hour. The SeptiCyte Rapid test is different from almost all other sepsis tests on the market by means of its operation directly…
Read MoreA multi-site study confirms the use of undiluted EDTA blood for the SeptiCyte RAPID sepsis assay
Data Validating EDTA Blood as Sample Type for SeptiCyte® RAPID Presented at the Association for Molecular Pathology 2022 Annual Meeting SEATTLE and BRISBANE, Australia, Nov. 3, 2022 /PRNewswire/ — Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, announced today the presentation of an abstract at the Association for Molecular Pathology 2022 Annual Meeting…
Read MoreContagionLive interview: A Rapid Sepsis Diagnostic Test for Better Patient Outcomes
Nina Cosdon of ContagionLive interviewed the chief medical officer of Immunexpress Inc., Roy Davis, MD, PhD, MHA, in a post titled A Rapid Sepsis Diagnostic Test for Better Patient Outcomes. Sepsis diagnosis often takes days. Dr. Roy Davis and his team have developed a test that can diagnose sepsis in an hour. Sepsis is one of…
Read More